NEXALIN TECHNOLOGY INC (NXL)

Company Profile

Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Laguna Niguel, California and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Company Info

NEXALIN TECHNOLOGY INC

26072 Merit Circle, Suite 106

Laguna Niguel CALIFORNIA

P: 19492608090

Employees: 6

Website: https://nexalin.com